Researchers sought to examine whether patients with COVID-19 receiving steroids develop new-onset atrial fibrillation.
Investigators performed a retrospective observational study to determine if long-term use of beta-blockers is associated with risk for recurrent ischemic events or all-cause mortality.
In a study presented at AHA 2021, researchers aimed to assess the link between cancer therapy-related cardiac dysfunction and immune checkpoint inhibitors.
In a landmark trial presented at AHA 2021, researchers aimed to understand the safety and efficacy of direct oral anticoagulants vs vitamin K antagonists in Black patients with non-valvular atrial fibrillation and venous thromboembolism.
Research presented at AHA 2021 showed that a certain biomarker could potentially help with the early diagnosis of non-ST-segment elevation acute coronary syndrome.
Investigators assessed the impact of diabetes mellitus on the efficacy of a low-dose, triple combination, polypill or standard care for the treatment of hypertension.
Patients with ACS who underwent percutaneous coronary intervention benefited from a genotype-guided P2Y12 inhibitor antiplatelet strategy.
A network meta-analysis was done to compare the effectiveness of SGLT2 inhibitors in participants with type 2 diabetes and cardiovascular risk factors.
Researchers at AHA 2021 presented a study that examined rates of hypertensive crisis in young cannabis users vs nonusers of different race and sex.
Researchers at AHA 2021 presented a study that sought to determine whether high leptin affects the risk for mortality or morbidity in patients with stable CHD.
A nationwide registry-based study presented at AHA 2021 finds that ticagrelor is associated with a lower risk of bleeding after PCI for ACS.
Researchers reported their findings on the effects of antihypertensive dosing in morning vs evening on patient prognosis at AHA 2021.
Among patients with type 2 diabetes, empagliflozin showed greater benefits in patients with CVD vs without.
Researchers aimed to study the effects of DAT alone or TAT for 1 month or 6 months in patients who previously underwent primary percutaneous coronary intervention.
Researchers at AHA 2021 presented their findings from a study that compared CVD risk factors and in-hospital outcomes in young, Black US adults a decade apart.